XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Beginning balance at Dec. 31, 2019 $ 440,826 $ 1,968 $ 44,564,674 $ (102,625) $ (44,023,191)
Beginning balance (in shares) at Dec. 31, 2019   19,683,401      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 160,841   160,841    
Issuance of common stock 5,222,687 $ 331 5,222,356    
Issuance of common stock (in shares)   3,308,003      
Issuance of common stock from the exercise of warrants 1,665,020 $ 170 1,664,850    
Issuance of common stock from the exercise of warrants (in shares)   1,699,000      
Stock options exercised 1 $ 1      
Stock options exercised (in shares)   10,149      
Net loss (4,252,248)       (4,252,248)
Foreign currency translation adjustments (22,944)     (22,944)  
Ending balance at Mar. 31, 2020 3,214,183 $ 2,470 51,612,721 (125,569) (48,275,439)
Ending balance (in shares) at Mar. 31, 2020   24,700,553      
Beginning balance at Dec. 31, 2020 (1,151,733) $ 4,159 70,366,293 (91,388) (71,430,797)
Beginning balance (in shares) at Dec. 31, 2020   41,596,253      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 365,911   365,911    
Issuance of common stock 11,324,140 $ 567 11,323,573    
Issuance of common stock (in shares)   5,664,069      
Issuance of common stock from the exercise of warrants 50,400 $ 5 50,395    
Issuance of common stock from the exercise of warrants (in shares)   52,500      
Net loss (7,323,644)        
Foreign currency translation adjustments (6,841)     (6,841)  
Ending balance at Mar. 31, 2021 $ 3,258,233 $ 4,731 $ 82,106,172 $ (98,229) $ (78,754,441)
Ending balance (in shares) at Mar. 31, 2021   47,312,822